Granulocyte-colony stimulating factor as a treatment for diabetic neuropathy in rat

Kim, Kyung Soo; Song, Yi; Jin, Jian; Joe, Jun Ho; So, Byung Im; Park, Jun Yong; Fang, Cheng Hu; Kim, Mi Jung; Cho, Youl Hee; Hwang, Se Jin; Ro, Young Suck; Kim, Hyuck; Ahn, You Hern; Sung, Hak Joon; Sung, Jung Joon; Park, Shin Young; Lipton, Stuart A.

doi:10.1016/j.mce.2015.07.014

Cited by 10 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its neuroprotective and neuroregenerative potential as well as its antiapoptotic and anti-inflammatory properties has been acknowledged and demonstrated in human studies [50][51][52][53]. Early systemic hG-CSF treatment attenuates neuropathic pain after peripheral nerve injury through activation of mu opioid receptors on the injured nerve [54], induces swift pain relief in diabetic foot gangrene in humans [55], and promotes a dramatic therapeutic effect on a rodent model of diabetic neuropathy, which was attributed, at least in part, to the actions of bone marrow-derived cells [56]. In concordance to the above results, early and sustained relief in pain was a significant finding in the present study followed by improvements in function as the latter may be compromised by excess pain.…”

Section: Discussionmentioning

confidence: 99%

Avoidance of total knee arthroplasty in early osteoarthritis of the knee with intra-articular implantation of autologous activated peripheral blood stem cells versus hyaluronic acid: A randomized controlled trial with differential effects of growth factor addition

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Avoidance of total knee arthroplasty in early osteoarthritis of the knee with intra-articular implantation of autologous activated peripheral blood stem cells versus hyaluronic acid: A randomized controlled trial with differential effects of growth factor addition

et al. 2017

View full text Add to dashboard Cite

“…In a rodent model of DNP, intraperitoneal administration of G-CSF improved nerve function, preventing axonal atrophy and demyelination, mainly due to peri-neuronal recruitment of stem cells from BM. However, no fusion with recipient cells or proof of BM cell differentiation into neurons was observed, thus suggesting a paracrine action by recruited cells [ 55 ].…”

Section: The Upside: Evidence For Bm-derived Stem Cells Improving Diamentioning

confidence: 99%

Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications

Mangialardi

Madeddu

2016

Curr Diab Rep

View full text Add to dashboard Cite

Diabetes is one of the main economic burdens in health care, which threatens to worsen dramatically if prevalence forecasts are correct. What makes diabetes harmful is the multi-organ distribution of its microvascular and macrovascular complications. Regenerative medicine with cellular therapy could be the dam against life-threatening or life-altering complications. Bone marrow-derived stem cells are putative candidates to achieve this goal. Unfortunately, the bone marrow itself is affected by diabetes, as it can develop a microangiopathy and neuropathy similar to other body tissues. Neuropathy leads to impaired stem cell mobilization from marrow, the so-called mobilopathy. Here, we review the role of bone marrow-derived stem cells in diabetes: how they are affected by compromised bone marrow integrity, how they contribute to other diabetic complications, and how they can be used as a treatment for these. Eventually, we suggest new tactics to optimize stem cell therapy.

show abstract

“…Its neuroprotective and neuroregenerative potential as well as its antiapoptotic and anti-inflammatory properties has been acknowledged and demonstrated in human studies [ 50 – 53 ]. Early systemic hG-CSF treatment attenuates neuropathic pain after peripheral nerve injury through activation of mu opioid receptors on the injured nerve [ 54 ], induces swift pain relief in diabetic foot gangrene in humans [ 55 ], and promotes a dramatic therapeutic effect on a rodent model of diabetic neuropathy, which was attributed, at least in part, to the actions of bone marrow-derived cells [ 56 ]. In concordance to the above results, early and sustained relief in pain was a significant finding in the present study followed by improvements in function as the latter may be compromised by excess pain.…”

Section: Discussionmentioning

confidence: 99%

Avoidance of Total Knee Arthroplasty in Early Osteoarthritis of the Knee with Intra-Articular Implantation of Autologous Activated Peripheral Blood Stem Cells versus Hyaluronic Acid: A Randomized Controlled Trial with Differential Effects of Growth Factor Addition

Turajane

Chaveewanakorn

Fongsarun

et al. 2017

Stem Cells International

View full text Add to dashboard Cite

In this randomized controlled trial, in early osteoarthritis (OA) that failed conservative intervention, the need for total knee arthroplasty (TKA) and WOMAC scores were evaluated, following a combination of arthroscopic microdrilling mesenchymal cell stimulation (MCS) and repeated intra-articular (IA) autologous activated peripheral blood stem cells (AAPBSCs) with growth factor addition (GFA) and hyaluronic acid (HA) versus IA-HA alone. Leukapheresis-harvested AAPBSCs were administered as three weekly IA injections combined with HA and GFA (platelet-rich plasma [PRP] and granulocyte colony-stimulating factor [hG-CSF]) and MCS in group 1 and in group 2 but without hG-CSF while group 3 received IA-HA alone. Each group of 20 patients was evaluated at baseline and at 1, 6, and, 12 months. At 12 months, all patients in the AAPBSC groups were surgical intervention free compared to three patients needing TKA in group 3 (p < 0.033). Total WOMAC scores showed statistically significant improvements at 6 and 12 months for the AAPBSC groups versus controls. There were no notable adverse events. We have shown avoidance of TKA in the AAPBSC groups at 12 months and potent, early, and sustained symptom alleviation through GFA versus HA alone. Differential effects of hG-CSF were noted with an earlier onset of symptom alleviation throughout.

show abstract

Granulocyte-colony stimulating factor as a treatment for diabetic neuropathy in rat

Cited by 10 publications

References 35 publications

Avoidance of total knee arthroplasty in early osteoarthritis of the knee with intra-articular implantation of autologous activated peripheral blood stem cells versus hyaluronic acid: A randomized controlled trial with differential effects of growth factor addition

Avoidance of total knee arthroplasty in early osteoarthritis of the knee with intra-articular implantation of autologous activated peripheral blood stem cells versus hyaluronic acid: A randomized controlled trial with differential effects of growth factor addition

Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications

Avoidance of Total Knee Arthroplasty in Early Osteoarthritis of the Knee with Intra-Articular Implantation of Autologous Activated Peripheral Blood Stem Cells versus Hyaluronic Acid: A Randomized Controlled Trial with Differential Effects of Growth Factor Addition

Contact Info

Product

Resources

About